Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT07446439

Obesity & weight · Phase 3 · Recruiting now

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

NCT07446439 · Sponsor: Vanda Pharmaceuticals

What this trial means for you

This study is recruiting now at 10 US sites. It's studying Tradipitant, Placebo for nausea and vomiting, obesity.

Who can joinAll sexes, 18 Years – 65 Years
Healthy volunteersAccepted
What you'd takeTradipitant, Placebo
Study length~8 months overall
Planned participants280
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Body Mass Index ≥ 25 and \< 40 kg/m\^2 * No serious medical problems or chronic diseases, specifically no type I or type II diabetes Exclusion Criteria: * Another disorder that contributes to gastrointestinal symptoms * History of intolerance and/or hypersensitivity to NK-1 receptor antagonists * History of intolerance and/or hypersensitivity to GLP-1 receptor agonists * Exposure to any investigational medication within the past 60 days

Study sites by state

California

  • Vanda Investigational Site — Los Angeles · Recruiting now
  • Vanda Investigational Site — San Diego · Recruiting now
  • Vanda Investigational Site — San Jose · Opening soon

Florida

  • Vanda Investigational Site — Tampa · Recruiting now

New Jersey

  • Vanda Investigational Site — Hamilton · Opening soon

New York

  • Vanda Investigational Site — New York · Opening soon
  • Vanda Investigational Site — Syosset · Opening soon

Texas

  • Vanda Investigational Site — Plano · Opening soon
  • Vanda Investigational Site — San Antonio · Opening soon

Virginia

  • Vanda Investigational Site — Burke · Opening soon

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth